

chain nodes :

7 8 9 11 12 13 14 15

ring nodes :

1 2 3 4 5 6 10

chain bonds :

2-7 5-15 7-8 7-9 7-10 10-11 11-12 11-13 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 4-5 5-6 7-8 7-9 7-10 11-12 11-13 13-14

exact bonds :

5-15 10-11

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

10/700202

=> s 11
SAMPLE SEARCH INITIATED 11:57:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 68 TO ITERATE

100.0% PROCESSED 68 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 866 TO 1854
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s 11 sss full
FULL SEARCH INITIATED 11:58:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1413 TO ITERATE

100.0% PROCESSED 1413 ITERATIONS 103 ANSWERS
SEARCH TIME: 00.00.01

L3 103 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
161.76 161.97

FILE 'CAPLUS' ENTERED AT 11:58:27 ON 28 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Nov 2005 VOL 143 ISS 23
FILE LAST UPDATED: 27 Nov 2005 (20051127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 4 L3

=> d 14 1-4 bib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:1028086 CAPLUS
DN 143:326396



10/700202

TI Preparation of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
IN McDonald, Joseph J.; Kassab, Darren J.; Massa, Mark A.; Grapperhaus, Margaret L.; Schmidt, Michelle A.; Rico, Joseph G.; Mullins, Patrick B.; Brown, David L.
PA USA
SO U.S. Pat. Appl. Publ., 417 pp., Cont.-in-part of U.S. Ser. No. 618,288.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

App's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005209278	A1	20050922	US 2003-700202	20031103
	US 2005009838	A1	20050113	US 2003-618288	20030425
	WO 2005042521	A2	20050512	WO 2004-US36666	20041103
	WO 2005042521	A3	20050707		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
PRAI	US 2002-375598P	P	20020425		
	US 2002-380713P	P	20020515		
	US 2002-392021P	P	20020627		
	US 2003-618288	A2	20030425		
	US 2003-700202	A	20031103		

GI



AB Title compds. I [A1 and A2 together with the C to which they are bonded join to form (un)substituted heterocyclyl or carbocyclyl, or A1 and A2 are independently selected from H, alkyl, alkoxyalkyl, alkenyl, alkynyl, etc.; Rx = H, halo, CN, OH, NO₂, alkyl, alkenyl, alkoxy, alkoxyalkyl,

heterocyclyl, etc.; Y = N, CH, or CRx; E1 = (un)substituted carbocyclyl, heterocyclyl, etc.; E2 = O, CO, C(O)O, OC(O), bond, S, etc.; E3 = halo, CN, (un)substituted alkyl, alkenyl, alkynyl, heterocyclyl, heterocyclalkyl, etc.] and their pharmaceutically acceptable salts are prepd. and disclosed as protease inhibitors. E.g., a multi-step synthesis of II, starting from Et crotyl phosphonate and tert-Bu 4-[(4-formylpiperidin-1-yl)sulfonyl]tetrahydro-2H-pyran-2H-pyran-4-carboxylate, was given. This invention is directed generally to proteinase (also known as 'protease') inhibitors, and more particularly, inhibitors of matrix metalloproteinase (also known as 'matrix metalloprotease' or 'MMP'), aggrecanase, or TNF-.alpha. convertase activity. In assays to det. inhibition consts. (Ki) against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14, I possessed values ranging from 0.13->10,000. This invention also is directed to compns. of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathol. conditions) assocd. with MMP, aggrecanase, or TNF-.alpha. convertase activity.


IT	622387-48-8P	622389-78-0P	622390-02-7P
	622390-05-0P	622390-07-2P	622390-55-0P
	622390-62-9P	622390-68-5P	622390-72-1P
	622390-78-7P	622390-81-2P	622390-88-9P
	622390-93-6P	622390-99-2P	622391-09-7P
	622391-15-5P	622391-31-5P	622391-35-9P
	622391-39-3P	622391-43-9P	622391-83-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepns. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)


RN 622387-48-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-octyl-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622389-78-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-[(phenylmethoxy)methyl]-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-02-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-[(2,2,3,3-tetrafluoropropoxy)methyl]-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622390-05-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[(trifluoromethyl)phenyl]methoxy]methyl]-1-piperidinylsulfonyl- (9CI) (CA INDEX NAME)




10/700202

RN 622390-07-2 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(1Z)-1-octenyl-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622390-55-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[5-(2,2,2-trifluoroethoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-62-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-(5-ethoxypentyl)-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-68-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-(4-propoxypicolyl)-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-72-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-(4,4,4-trifluorobutoxy)butyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-78-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(hexyloxy)methyl]-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-81-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4,4,4-trifluorobutoxy)methyl]-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-88-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(6,6,6-trifluorohexyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-93-6 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-(2-butoxyethyl)-1-piperidinyl)sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI)
(CA INDEX NAME)



RN 622390-99-2 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[2-(4,4,4-trifluorobutoxy)ethyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



10/700202


RN 622391-09-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[4-(3,3,3-trifluoropropoxy)butyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622391-15-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-[2-(pentyloxy)ethyl]-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-31-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-(7,7,8,8,8-pentafluorooctyl)-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-35-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-(8,8,8-trifluoroctyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 622391-39-3 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-(5,5,6,6,6-pentafluorohexyl)-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



10/700202


RN 622391-43-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(6,6,7,7,7-pentafluoroheptyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622391-83-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 622382-02-9P 622385-57-3P 622385-59-5P
622385-60-8P 622385-61-9P 622385-62-0P
622385-88-0P 622385-89-1P 622385-90-4P
622385-91-5P 622385-92-6P 622387-62-6P
622387-72-8P 622387-73-9P 622387-74-0P
622387-75-1P 622387-76-2P 622387-77-3P
622387-78-4P 622387-79-5P 622387-80-8P
622387-81-9P 622387-82-0P 622387-83-1P
622387-84-2P 622387-92-2P 622387-94-4P
622387-96-6P 622387-98-8P 622388-18-5P
622388-35-6P 622388-36-7P 622388-37-8P
622388-38-9P 622388-40-3P 622388-42-5P
622388-44-7P 622388-46-9P 622388-47-0P
622388-48-1P 622388-50-5P 622388-51-6P
622388-52-7P 622388-53-8P 622388-54-9P
622388-55-0P 622388-56-1P 622388-57-2P
622388-58-3P 622388-60-7P 622388-61-8P


622388-62-9P 622388-63-0P 622388-67-4P
 622388-72-1P 622388-75-4P 622388-76-5P
 622388-79-8P 622389-05-3P 622389-06-4P
 622389-07-5P 622389-08-6P 622389-09-7P
 622389-10-0P 622389-11-1P 622389-12-2P
 622389-24-6P 622389-27-9P 622389-50-8P
 622389-73-5P 851771-04-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)


RN 622382-02-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-octyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-57-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(phenylmethoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-59-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(2,2,3,3-tetrafluoropropoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-60-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(2,2,3,3,3-pentafluoropropoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-61-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(2,2,3,3,4,4,4-heptafluorobutoxy)methyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 622385-62-0 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(2,2,3,3,4,4,5,5-octafluoropentyl)oxy]methyl]-1-piperidinyl]sulfonyl- (9CI) (CA INDEX NAME)



RN 622385-88-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(1Z)-1-octenyl-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622385-89-1 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(1E)-1-octenyl-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622385-90-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-91-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-92-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[[4-[(trifluoromethyl)thio]phenyl]methoxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-62-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(2,2,2-trifluoroethoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-72-8 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-(3-butoxypropyl)-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-73-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[3-(4,4,4-trifluorobutoxy)propyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-74-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[5-(3,3,3-trifluoropropoxy)pentyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-75-1 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[(4-(5-ethoxypentyl)-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-76-2 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(4-propoxybutyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-77-3 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[4-(4,4,4-trifluorobutoxy)butyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-78-4 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4-hexyloxy)methyl]-1-[(4-hexyloxy)methylsulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-79-5 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(4,4,4-trifluorobutoxy)methyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-80-8 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(6,6,6-trifluorohexyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-81-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(2-butoxyethyl)-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 622387-82-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[2-(4,4,4-trifluorobutoxy)ethyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-83-1 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(3,3,3-trifluoropropoxy)butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-84-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[2-(pentyloxy)ethyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-92-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(7,7,8,8,8-pentafluoroctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-94-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(8,8,8-trifluorooctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-96-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(5,5,6,6,6-pentafluorohexyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-98-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(6,6,7,7,7-pentafluoroheptyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-18-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622388-35-6 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(3,4-dihydro-2(1H)-isoquinolinyl)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 622388-36-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(3,4-dihydro-2(1H)-isoquinolinyl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-37-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-oxo-5-(4-phenyl-1-piperazinyl)-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-38-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-[methyl(2-methylpropyl)amino]-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-40-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-oxo-5-(1-piperidinyl)-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-42-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(cyclohexylmethylamino)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-44-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(2,3-dihydro-1H-indol-1-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622388-46-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 622388-47-0 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(1,3-dihydro-2H-isoindol-2-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622388-48-1 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-2-propynyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622388-50-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(5-(4-morpholinyl)-5-oxopentyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622388-51-6 CAPLUS


CN 4-Piperidinepentanamide, N-methyl-1-[[tetrahydro-4-

[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl] - (9CI) (CA INDEX NAME)




RN 622388-52-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(1,3-dihydro-2H-isoindol-2-yl)-5-oxopentyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622388-53-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(5-octahydro-2H-isoindol-2-yl)-5-oxopentyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-54-9 CAPLUS

CN 4-Piperidinepentanamide, 1-[(tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl)sulfonyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 622388-55-0 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-(2-methylpropyl)-1-[(tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-56-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(1-piperidinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-57-2 CAPLUS

CN 4-Piperidinepentanamide, N-(4-fluorophenyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-58-3 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-phenyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-60-7 CAPLUS

CN 4-Piperidinepentanamide, N-cyclohexyl-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-61-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(1-pyrrolidinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-62-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(4-phenyl-1-piperazinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-63-0 CAPLUS

CN 4-Piperidinepentanamide, N-(2-furanylmethyl)-N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-67-4 CAPLUS

CN 4-Piperidinpentanoic acid, 1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 622388-72-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(oxo-2-thienylacetyl)amino]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-75-4 CAPLUS

CN 4-Piperidinebutanamide, N-(cyclohexylmethyl)-N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-76-5 CAPLUS

CN 4-Piperidinpentanamide, N-(cyclohexylmethyl)-N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-79-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[4-[(1-phenylcyclopropyl)carbonyl]amino]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-05-3 CAPLUS

CN 4-Piperidinebutanamide, N-(2-furanylmethyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-06-4 CAPLUS

CN 4-Piperidinebutanamide, N-methyl-N-(4-methylphenyl)-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-07-5 CAPLUS

CN 4-Piperidinebutanamide, N-methyl-N-phenyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-08-6 CAPLUS

CN 4-Piperidinebutanamide, N-cyclohexyl-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-09-7 CAPLUS

CN 4-Piperidinebutanamide, N-phenyl-N-propyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-10-0 CAPLUS

CN 4-Piperidinebutanamide, N-(4-fluorophenyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-11-1 CAPLUS

CN 4-Piperidinebutanamide, N-ethyl-N-phenyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-12-2 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[(tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 622389-24-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]propyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-27-9 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-1-[(tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 622389-50-8 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(2-phenylethyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622389-73-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(1E,3E)-5-(4-morpholinyl)-5-oxo-1,3-pentadienyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 851771-04-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(5-(2,3-dihydro-1H-indol-1-yl)-5-oxopentyl)-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




IT 851771-07-8P 851771-08-9P 851771-09-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)


RN 851771-07-8 CAPLUS

CN 4-Piperidinpentanoic acid, 1-[[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2H-pyran-4-yl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 851771-08-9 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[[tetrahydro-4-[[[tetrahydro-2H-pyran-2-yl]oxy]amino]carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851771-09-0 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[[5-(2,3-dihydro-1H-indol-1-yl)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:409509 CAPLUS
 DN 142:463765
 TI Preparation of piperidinyl- and piperazinylsulfonylmethyl hydroxamic acids and their use as protease inhibitors
 IN Brown, David L.; Grapperhaus, Margaret L.; Kassab, Darren J.; Massa, Mark A.; McDonald, Joseph J.; Mullins, Patrick B.; Rico, Joseph G.; Schmidt, Michelle A.
 PA Pharmacia Corporation, USA
 SO PCT Int. Appl., 644 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

SAME IE

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042521	A2	20050512	WO 2004-US36666	20041103
	WO 2005042521	A3	20050707		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2005209278	A1	20050922	US 2003-700202	20031103
	US 2003-700202	A	20031103		
	US 2002-375598P	P	20020425		
	US 2002-380713P	P	20020515		
	US 2002-392021P	P	20020627		
	US 2003-618288	A2	20030425		
OS	MARPAT 142:463765				
GI					

parent



I

AB Title compds. I [A1-2 = H, alkyl, alkoxyalkyl, etc.; Rx = halo, CN, OH, NO₂, etc.; E2 = CO, COO, OCO, amino, etc.; E3 = alkyl, alkenyl, alkynyl, etc.] are prep'd. For instance, 4-[(4-(5-butylypyrazin-2-yl)piperazin-1-yl)sulfonyl]-N-(hydroxy)tetrahydro-2H-pyran-4-carboxamide.bul.2HCl (II) is prep'd. in 8 steps from 1-(tert-butoxycarbonyl)piperazine, 2-chloropyrazine, butylmagnesium chloride, bis(2-bromoethyl)ether and O-(tetrahydro-2H-pyran-2-yl)hydroxyamine. II exhibits Ki = >10,000 nM for MMP-1, 1.52 nM for MMP-2, 0.696 nM for MMP-9, 1.82 nM for MMP-13 and 4290 nM for MMP-14. I are useful for the treatment of conditions assoc'd. with MMP activity and/or aggrecanase activity.


IT 622387-48-8P 622389-78-0P 622390-02-7P
 622390-05-0P 622390-07-2P 622390-55-0P
 622390-62-9P 622390-68-5P 622390-72-1P
 622390-78-7P 622390-81-2P 622390-88-9P
 622390-93-6P 622390-99-2P 622391-09-7P
 622391-15-5P 622391-31-5P 622391-35-9P
 622391-39-3P 622391-43-9P 622391-83-7P
 851771-02-3P 851771-07-8P 851771-08-9P
 851771-09-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)


RN 622387-48-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-octyl-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622389-78-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-[(phenylmethoxy)methyl]-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-02-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-[(2,2,3,3-tetrafluoropropoxy)methyl]-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622390-05-0 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[[4-(trifluoromethyl)phenyl]methoxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622390-07-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-(1Z)-1-octenyl-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622390-55-0 CAPLUS


10/700202

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[5-(2,2,2-trifluoroethoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-62-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-(5-ethoxypentyl)-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-68-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(4-propoxybutyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-72-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-(4,4,4-trifluorobutoxy)butyl]-1-piperidinyl]sulfonyl] (9CI) (CA INDEX NAME)




RN 622390-78-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(hexyloxy)methyl]-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-81-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[(4,4,4-trifluorobutoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-88-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[(6,6,6-trifluorohexyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-93-6 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-(2-butoxyethyl)-1-piperidinyl)sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-99-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[2-(4,4,4-trifluorobutoxy)ethyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 622391-09-7 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[3,3,3-trifluoropropoxy]butyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



10/700202


RN 622391-15-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-[2-(pentyloxy)ethyl]-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-31-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(7,7,8,8,8-pentafluorooctyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-35-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-(8,8,8-trifluorooctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622391-39-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(5,5,6,6,6-pentafluorohexyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-43-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(6,6,7,7,7-pentafluoroheptyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622391-83-7 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851771-02-3 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(1E)-1-octenyl-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 851771-07-8 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[tetrahydro-4-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2H-pyran-4-yl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 851771-08-9 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[[tetrahydro-4-[[[tetrahydro-2H-pyran-2-yl]oxy]amino]carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851771-09-0 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(2,3-dihydro-1H-indol-1-yl)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



IT 622382-02-9P 622385-57-3P 622385-59-5P


622385-60-8P 622385-61-9P 622385-62-0P
 622385-88-0P 622385-89-1P 622385-90-4P
 622385-91-5P 622385-92-6P 622387-62-6P
 622387-72-8P 622387-73-9P 622387-74-0P
 622387-75-1P 622387-76-2P 622387-77-3P
 622387-78-4P 622387-79-5P 622387-80-8P
 622387-81-9P 622387-82-0P 622387-83-1P
 622387-84-2P 622387-92-2P 622387-94-4P
 622387-96-6P 622387-98-8P 622388-18-5P
 622388-35-6P 622388-36-7P 622388-37-8P
 622388-38-9P 622388-40-3P 622388-42-5P
 622388-44-7P 622388-46-9P 622388-47-0P
 622388-48-1P 622388-50-5P 622388-51-6P
 622388-52-7P 622388-53-8P 622388-54-9P
 622388-55-0P 622388-56-1P 622388-57-2P
 622388-58-3P 622388-60-7P 622388-61-8P
 622388-62-9P 622388-63-0P 622388-67-4P
 622388-72-1P 622388-75-4P 622388-76-5P
 622388-79-8P 622389-05-3P 622389-06-4P
 622389-07-5P 622389-08-6P 622389-09-7P
 622389-10-0P 622389-11-1P 622389-12-2P
 622389-24-6P 622389-27-9P 622389-50-8P
 622389-73-5P 851771-04-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids
 and their use as matrix metalloproteinase inhibitors)


RN 622382-02-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-octyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-57-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(phenylmethoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-59-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(2,2,3,3-tetrafluoropropoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-60-8 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(2,2,3,3,3-pentafluoropropoxy)methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622385-61-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-[(2,2,3,3,4,4,4-heptafluorobutoxy)methyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622385-62-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(2,2,3,3,4,4,5,5-octafluoropentyl)oxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622385-88-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(1Z)-1-octenyl-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622385-89-1 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(1E)-1-octenyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622385-90-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[[4-(trifluoromethyl)phenyl]methoxy]methyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)



RN 622385-91-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[[4-(trifluoromethoxy)phenyl]methoxy]methyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)



RN 622385-92-6 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[[4-(trifluoromethyl)thio]phenyl]methoxy]methyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)




RN 622387-62-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(2,2,2-trifluoroethoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-72-8 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-(3-butoxypropyl)-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-73-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-(4,4,4-trifluorobutoxy)propyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-74-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(3,3,3-trifluoropropoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-75-1 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-(5-ethoxypentyl)-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-76-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(4-propoxypentyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-77-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(4,4,4-trifluorobutoxy)butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-78-4 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(hexyloxy)methyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-79-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(4,4,4-trifluorobutoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-80-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(6,6,6-trifluorohexyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-81-9 CAPLUS

CN · 2H-Pyran-4-carboxamide, 4-[(4-(2-butoxyethyl)-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-82-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[2-(4,4,4-trifluorobutoxy)ethyl]-1-piperidinyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622387-83-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(3,3,3-trifluoropropoxy)butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-84-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[2-(pentyloxy)ethyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-92-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(7,7,8,8,8-pentafluoroctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-94-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(8,8,8-trifluorooctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-96-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(5,5,6,6,6-pentafluorohexyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-98-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(6,6,7,7,7-pentafluoroheptyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-18-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622388-35-6 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(3,4-dihydro-2(1H)-isoquinoliny)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 622388-36-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(3,4-dihydro-2(1H)-isoquinolinyl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-37-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-oxo-5-(4-phenyl-1-piperazinyl)-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-38-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-oxo-5-[methyl(2-methylpropyl)amino]-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-40-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(1E,3E)-5-oxo-5-(1-piperidinyl)-1,3-pentadienyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-42-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(1E,3E)-5-(cyclohexylmethylamino)-5-oxo-1,3-pentadienyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-44-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(1E,3E)-5-(2,3-dihydro-1H-indol-1-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622388-46-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 622388-47-0 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(1,3-dihydro-2H-isoindol-2-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622388-48-1 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-2-propynyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-50-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(5-(4-morpholinyl)-5-oxopentyl)-1-piperidinyl]sulfonyl)- (9CI) (CA INDEX NAME)




RN 622388-51-6 CAPLUS

CN 4-Piperidinpentanamide, N-methyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl)-2H-pyran-4-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 622388-52-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(5-(1,3-dihydro-2H-isoindol-2-yl)-5-oxopentyl)-1-piperidinyl]sulfonyl)tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622388-53-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(5-(octahydro-2H-isoindol-2-yl)-5-oxopentyl)-1-piperidinyl]sulfonyl)- (9CI) (CA INDEX NAME)




RN 622388-54-9 CAPLUS

CN 4-Piperidinepentanamide, 1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 622388-55-0 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-(2-methylpropyl)-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-56-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(1-piperidinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-57-2 CAPLUS

CN 4-Piperidinepentanamide, N-(4-fluorophenyl)-N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-58-3 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-phenyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 622388-60-7 CAPLUS

CN 4-Piperidinepentanamide, N-cyclohexyl-N-methyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 622388-61-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(5-oxo-5-(1-pyrrolidinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-62-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(4-phenyl-1-piperazinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-63-0 CAPLUS

CN 4-Piperidinepentanamide, N-(2-furanylmethyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-67-4 CAPLUS


CN 4-Piperidinepentanoic acid, 1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 622388-72-1 CAPLUS
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[4-[(oxo-2-thienylacetyl)amino]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-75-4 CAPLUS
 CN 4-Piperidinebutanamide, N-(cyclohexylmethyl)-N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622388-76-5 CAPLUS
 CN 4-Piperidinepentanamide, N-(cyclohexylmethyl)-N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-79-8 CAPLUS
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[4-[[1-phenylcyclopropyl]carbonyl]amino]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-05-3 CAPLUS

CN 4-Piperidinebutanamide, N-(2-furanylmethyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-06-4 CAPLUS

CN 4-Piperidinebutanamide, N-methyl-N-(4-methylphenyl)-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-07-5 CAPLUS

CN 4-Piperidinebutanamide, N-methyl-N-phenyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-08-6 CAPLUS

CN 4-Piperidinebutanamide, N-cyclohexyl-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-09-7 CAPLUS

CN 4-Piperidinebutanamide, N-phenyl-N-propyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-ylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-10-0 CAPLUS

CN 4-Piperidinebutanamide, N-(4-fluorophenyl)-N-methyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-ylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-11-1 CAPLUS

CN 4-Piperidinebutanamide, N-ethyl-N-phenyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-ylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-12-2 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-ylsulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 622389-24-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]propyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-27-9 CAPLUS

CN 4-Piperidinpentanamide, N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 622389-50-8 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(2-phenylethyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622389-73-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-(4-morpholinyl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 851771-04-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[[5-(2,3-dihydro-1H-indol-1-yl)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:875282 CAPLUS

DN 139:364961

TI Preparation of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Brown, David L.; Carroll, Jeffery N.; Chen, Yiyuan; Fobian, Yvette; Freskos, John N.; Gasiecki, Alan F.; Grapperhaus, Margaret; Heintz, Robert M.; Hockerman, Susan L.; Kassab, Darren J.; Khanna, Ish Kumar; Kolodziej, Stephen A.; Massa, Mark; McDonald, Joseph; Mischke, Brent V.; Mischke, Deborah A.; Mullins, Patrick B.; Nagy, Mark; Norton, Monica B.; Rico, Joseph G.; Schmidt, Michelle A.; Stehle, Nathan W.; Talley, John J.; Vernier, William F.; Villamill, Clara I.; Wang, Lijuan Jane; Wynn, Thomas A.

PA Pharmacia Corporation, USA; et al.

SO PCT Int. Appl., 819 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091247	A2	20031106	WO 2003-US13123	20030425
	WO 2003091247	A3	20040115		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2483314	AA	20031106	CA 2003-2483314	20030425
EP 1501827	A2	20050202	EP 2003-718529	20030425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009671	A	20050503	BR 2003-9671	20030425
PRAI US 2002-375598P	P	20020425		
US 2002-380713P	P	20020515		
US 2002-392021P	P	20020627		
WO 2003-US13123	W	20030425		
OS MARPAT 139:364961				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A1 and A2 together with the C to which they are bonded join to form (un)substituted-heterocyclyl or -carbocyclyl, or A1 and A2 are independently selected from H, alkyl, alkoxyalkyl, alkenyl, alkynyl, etc.; Rx = H, halo, CN, OH, NO₂, alkyl, alkenyl, alkoxy, alkoxyalkyl, heterocyclyl, etc.; Y = N, CH, or CRx; E1 = (un)substituted heteroaryl; E2 = O, CO, C(O)O, OC(O), bond, S, etc.; E3 = halo, CN, (un)substituted-alkyl, -alkenyl, -alkynyl, -heterocyclyl, heterocyclylalkyl, etc.] and their pharmaceutically acceptable salts are prep'd. and disclosed as protease inhibitors. Thus, e.g., II.cndot.HCl was prep'd. with piperazine ring formation occurring via cyclization of 2,2,2-trifluoroethoxyaniline (prepn. given) with N,N-di(2-chloroethyl)methylsulfonamide (prepn. given) to provide piperazinyl intermediate III which was converted in five addnl. steps to the desired product. This invention is directed generally to proteinase (also known as 'protease') inhibitors, and more particularly, inhibitors of matrix metalloproteinase (also known as 'matrix metalloprotease' or 'MMP') activity and/or aggrecanase activity. In assays to det. inhibition consts. (Ki) against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14, I possessed values ranging from 0.13->10,000. This invention also is directed to compns. of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathol. conditions) assoc'd. with MMP activity and/or aggrecanase activity.

IT 622396-56-9P 622396-57-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compds.; prepn. of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)

RN 622396-56-9 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-(methyl-2-propynylamino)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 622396-57-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-(pentyloxy)propyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 622387-48-8P 622389-78-0P 622390-02-7P

622390-05-0P 622390-07-2P 622390-55-0P

622390-62-9P 622390-68-5P 622390-72-1P

622390-78-7P 622390-81-2P 622390-88-9P

622390-93-6P 622390-99-2P 622391-09-7P

622391-15-5P 622391-31-5P 622391-35-9P


622391-39-3P 622391-43-9P 622391-83-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)

RN 622387-48-8 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-octyl-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622389-78-0 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-[(phenylmethoxy)methyl]-1-

piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-02-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-[(2,2,3,3-tetrafluoropropoxy)methyl]-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622390-05-0 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[[4-[[4-(trifluoromethyl)phenyl]methoxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622390-07-2 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-(1Z)-1-octenyl-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 622390-55-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[5-(2,2,2-trifluoroethoxy)pentyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-62-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-(5-ethoxypentyl)-1-


10/700202

piperidinylsulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI)
(CA INDEX NAME)




RN 622390-68-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-(4-propoxypicolyl)-1-piperidinylsulfonyl]N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-72-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-(4,4,4-trifluorobutoxy)butyl)-1-piperidinylsulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-78-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[(hexyloxy)methyl]-1-piperidinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI)
(CA INDEX NAME)



RN 622390-81-2 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[(4,4,4-trifluorobutoxy)methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



10/700202


RN 622390-88-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-(6,6,6-trifluorohexyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622390-93-6 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-(2-butoxyethyl)-1-piperidinyl)sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622390-99-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-[2-(4,4,4-trifluorobutoxy)ethyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622391-09-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(4-(3,3,3-trifluoropropoxy)butyl)-1-piperidinyl]sulfonyl] - (9CI) (CA INDEX NAME)




RN 622391-15-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-[2-(pentyloxy)ethyl]-1-piperidinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)




RN 622391-31-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(7,7,8,8-pentafluoroctyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-35-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-(8,8,8-trifluoroctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622391-39-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(5,5,6,6,6-pentafluorohexyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 622391-43-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(6,6,7,7,7-pentafluoroheptyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 622391-83-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT 622382-02-9P 622385-57-3P 622385-59-5P
 622385-60-8P 622385-61-9P 622385-62-0P
 622385-88-0P 622385-89-1P 622385-90-4P
 622385-91-5P 622385-92-6P 622387-62-6P
 622387-72-8P 622387-73-9P 622387-74-0P
 622387-75-1P 622387-76-2P 622387-77-3P
 622387-78-4P 622387-79-5P 622387-80-8P
 622387-81-9P 622387-82-0P 622387-83-1P
 622387-84-2P 622387-92-2P 622387-94-4P
 622387-96-6P 622387-98-8P 622388-18-5P
 622388-35-6P 622388-36-7P 622388-37-8P
 622388-38-9P 622388-40-3P 622388-42-5P
 622388-44-7P 622388-46-9P 622388-47-0P
 622388-48-1P 622388-50-5P 622388-51-6P
 622388-52-7P 622388-53-8P 622388-54-9P
 622388-55-0P 622388-56-1P 622388-57-2P
 622388-58-3P 622388-60-7P 622388-61-8P
 622388-62-9P 622388-63-0P 622388-67-4P
 622388-72-1P 622388-75-4P 622388-76-5P
 622388-79-8P 622389-05-3P 622389-06-4P
 622389-07-5P 622389-08-6P 622389-09-7P
 622389-10-0P 622389-11-1P 622389-12-2P
 622389-24-6P 622389-27-9P 622389-50-8P
 622389-73-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)


RN 622382-02-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-octyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-57-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(phenylmethoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-59-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(2,2,3,3-tetrafluoropropoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-60-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(2,2,3,3,3-pentafluoropropoxy)methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-61-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(2,2,3,3,4,4,4-heptafluorobutoxy)methyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 622385-62-0 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[[[(2,2,3,3,4,4,4,5,5-octafluoropentyl)oxy]methyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622385-88-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(1Z)-1-octenyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622385-89-1 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(1E)-1-octenyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622385-90-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-91-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622385-92-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[[[4-(trifluoromethyl)thio]phenyl]methoxy]methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-62-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(2,2,2-trifluoroethoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-72-8 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-(3-butoxypropyl)-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-73-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-(4,4,4-trifluorobutoxy)propyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-74-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(3,3,3-trifluoropropoxy)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-75-1 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-(5-ethoxypentyl)-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-76-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(4-propoxypentyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-77-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(4-(4,4,4-trifluorobutoxy)butyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-78-4 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[(4-[(hexyloxy)methyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-79-5 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(4,4,4-trifluorobutoxy)methyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-80-8 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(6,6,6-trifluorohexyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 622387-81-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4-(2-butoxyethyl)-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622387-82-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(2-(4,4,4-trifluorobutoxy)ethyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-83-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(3,3,3-trifluoropropoxy)butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-84-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[2-(pentyloxy)ethyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-92-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(7,7,8,8,8-pentafluorooctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-94-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(8,8,8-trifluorooctyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-96-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(5,5,6,6,6-pentafluorohexyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622387-98-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(6,6,7,7,7-pentafluoroheptyl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-18-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622388-35-6 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(3,4-dihydro-2(1H)-isoquinolinyl)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 622388-36-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(1E,3E)-5-(3,4-dihydro-2(1H)-isoquinolinyl)-5-oxo-1,3-pentadienyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-37-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(1E,3E)-5-oxo-5-(4-phenyl-1-piperazinyl)-1,3-pentadienyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-38-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(1E,3E)-5-oxo-5-[methyl(2-methylpropyl)amino]-1,3-pentadienyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-40-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-[(1E,3E)-5-oxo-5-(1-piperidinyl)-1,3-pentadienyl]-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-42-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(1E,3E)-5-(cyclohexylmethylamino)-5-oxo-1,3-pentadienyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 622388-44-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[(4-[(1E,3E)-5-(2,3-dihydro-1H-indol-1-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622388-46-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 622388-47-0 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[(1E,3E)-5-(1,3-dihydro-2H-isoindol-2-yl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622388-48-1 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-2-propynyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-50-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(4-morpholinyl)-5-oxopentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-51-6 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-52-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(1,3-dihydro-2H-isoindol-2-yl)-5-oxopentyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622388-53-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(octahydro-2H-isoindol-2-yl)-5-oxopentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-54-9 CAPLUS

CN 4-Piperidinepentanamide, 1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 622388-55-0 CAPLUS

CN 4-Piperidinepentanamide, N-methyl-N-(2-methylpropyl)-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-56-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(1-piperidinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-57-2 CAPLUS

CN 4-Piperidinepentanamide, N-(4-fluorophenyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-58-3 CAPLUS

CN 4-Piperidinpentanamide, N-methyl-N-phenyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622388-60-7 CAPLUS

CN 4-Piperidinpentanamide, N-cyclohexyl-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622388-61-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(1-pyrrolidinyl)pentyl]-1-piperidinyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622388-62-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-oxo-5-(4-phenyl-1-piperazinyl)pentyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-63-0 CAPLUS

CN 4-Piperidinepentanamide, N-(2-furanyl methyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-67-4 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 622388-72-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(4-oxo-2-thienylacetyl)amino]butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-75-4 CAPLUS

CN 4-Piperidinebutanamide, N-(cyclohexylmethyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-76-5 CAPLUS

CN 4-Piperidinepentanamide, N-(cyclohexylmethyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622388-79-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(4-[(1-phenylcyclopropyl)carbonyl]amino)butyl]-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622389-05-3 CAPLUS

CN 4-Piperidinebutanamide, N-(2-furanylmethyl)-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-06-4 CAPLUS

CN 4-Piperidinebutanamide, N-methyl-N-(4-methylphenyl)-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-07-5 CAPLUS

CN 4-Piperidinebutanamide, N-methyl-N-phenyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-08-6 CAPLUS

CN 4-Piperidinebutanamide, N-cyclohexyl-N-methyl-1-[[tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 622389-09-7 CAPLUS

CN 4-Piperidinebutanamide, N-phenyl-N-propyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 622389-10-0 CAPLUS

CN 4-Piperidinebutanamide, N-(4-fluorophenyl)-N-methyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 622389-11-1 CAPLUS

CN 4-Piperidinebutanamide, N-ethyl-N-phenyl-1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 622389-12-2 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[(tetrahydro-4-(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl-, methyl ester (9CI) (CA INDEX NAME)




RN 622389-24-6 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]propyl]-1-piperidinyl]sulfonyl] (9CI) (CA INDEX NAME)




RN 622389-27-9 CAPLUS

CN 4-Piperidinpentanamide, N-methyl-1-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]-N-[4-(trifluoromethoxy)phenyl] (9CI) (CA INDEX NAME)



RN 622389-50-8 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(2-phenylethyl)-1-piperidinyl]sulfonyl] (9CI) (CA INDEX NAME)



RN 622389-73-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[(1E,3E)-5-(4-morpholinyl)-5-oxo-1,3-pentadienyl]-1-piperidinyl]sulfonyl] (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:553575 CAPLUS
 DN 133:164006
 TI Preparation of sulfamato hydroxamic acid metalloprotease inhibitors
 IN De Crescenzo, Gary A.; Rico, Joseph G.; Boehm, Terri L.; Carroll, Jeffery N.; Kassab, Darren J.; Mischke, Deborah A.
 PA G.D. Searle and Co., USA
 SO PCT Int. Appl., 628 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000046221	A1	20000810	WO 2000-US3061	20000207
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362230	AA	20000810	CA 2000-2362230	20000207
	EP 1157021	A1	20011128	EP 2000-905996	20000207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008440	A	20020326	BR 2000-8440	20000207
	US 6448250	B1	20020910	US 2000-499276	20000207
	JP 2002536373	T2	20021029	JP 2000-597291	20000207
	EE 200100410	A	20021216	EE 2001-410	20000207
	AU 775701	B2	20040812	AU 2000-27574	20000207
	US 6372758	B1	20020416	US 2001-884548	20010619
	NO 2001003850	A	20010919	NO 2001-3850	20010807
	BG 105788	A	20020228	BG 2001-105788	20010807
	ZA 2001006492	A	20030507	ZA 2001-6492	20010807
	US 6492367	B1	20021210	US 2002-84713	20020226
	US 6800646	B1	20041005	US 2002-262622	20020930
	US 2005049280	A1	20050303	US 2004-887450	20040708
PRAI	US 1999-119181P	P	19990208		
	US 2000-499276	A1	20000207		
	WO 2000-US3061	W	20000207		
	US 2002-84713	A3	20020226		
	US 2002-262622	A3	20020930		
OS	MARPAT 133:164006				
GI					



AB The title compds. $R20C(O)CR1R2SO2NR3aR3b$ (I) [wherein R1 and R2 taken together with the C to which they are attached = (un)substituted heterocyclyl or cycloalkyl; or R1 and R2 = independently H, (un)substituted (cyclo)alkyl, alkyloxylalkyl, alkylthioalkyl, alkenyl, alkynyl, aryl(alkyl), heterocyclyl(alkyl), etc.; R3a and R3b = independently H or (un)substituted alkyl, alkenyl, alkynyl, (hetero)aryl, heterocyclyl, cycloalkyl, or alkoxyalkyl; R20 = OH, alkoxy, aryloxy, NH-OR22, or NH-OR14; R22 = selectively removable protecting group, such as 2-THP, benzyl, trisubstituted silyl, α -NO2C6H4, etc.; R14 = H, a cation, or acyl] were prepd. as selective matrix metalloproteinase (MMP) inhibitors for the treatment of various conditions, such as pathol. breakdown of connective tissue, osteoarthritis, inflammation, tumor growth, and angiogenesis. Examples include the syntheses of over 50 piperidinylsulfonyl and piperazinylsulfonyl hydroxamic acids and their intermediates. In vitro MMP assay data for I show selective inhibition of MMP-2 and MMP-13 compared to MMP-1. Some inhibition assay data for MMP-3, MMP-7, MMP-8, MMP-9, and MMP-14 are also given. Thus, II was prepd. in a multi-step sequence involving addn. of $MeOC(O)Cl$ to 1-(methylsulfonyl)-4-(benzyloxy)piperidine (4-step prepn. given) to form the methylene sulfonamide, cycloaddn. of dibromodiethyl ether to give the THF-substituted sulfonamide, deesterification, addn. of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine to form the THP hydroxamate, and deprotection to yield the desired hydroxamic acid. II inhibited MMP-1, MMP-2, and MMP-13 with IC50 values of < 10,000 nM, 7.0 nM and 20.0 nM, resp.


IT 287952-41-4P 287954-44-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; prepn. of sulfamato hydroxamic acid metalloprotease inhibitors by cycloaddn. of dihalodialkyl ethers and amines to methylene sulfonamides followed by addn. of hydroxylamines)

RN 287952-41-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 287954-44-3 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[(4-[(3,5-dimethyl-1-piperidinyl)carbonyl]-1-piperidinyl)sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI)
(CA INDEX NAME)

IT 287951-55-7P 287951-75-1P 287951-95-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of sulfamato hydroxamic acid metalloprotease inhibitors by cycloaddn. of dihalodialkyl ethers and amines to methylene sulfonamides followed by addn. of hydroxylamines)

RN 287951-55-7 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-(phenylmethyl)-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 287951-75-1 CAPLUS

10/700202

CN 2H-Pyran-4-carboxamide, 4-[[4-[[[(3R,5S)-3,5-dimethyl-1-piperidinyl]carbonyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287951-95-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[[[(3R,5R)-3,5-dimethyl-1-piperidinyl]carbonyl]-1-piperidinyl]sulfonyl]tetrahydro-N-hydroxy-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.21	182.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

FILE 'CAOLD' ENTERED AT 11:59:12 ON 28 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts

10/700202

printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3
L5 0 L3

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	182.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.92

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:59:23 ON 28 NOV 2005